Evidence Hub

Research progress of artificial intelligence in high-throughput drug screening

Liu X, Ren X, Li P, Li X, Ren X, Sui C, Zhou H, Luo F et al.

Frontiers in pharmacology, 2026

1 citation

Abstract

High-throughput screening (HTS) is widely used in modern drug discovery. It enables batch activity testing of compounds and provides important support for the identification of active compounds. However, its screening efficiency and accuracy need to be improved. To address this issue, artificial intelligence (AI) has been gradually integrated into the HTS workflow. Leveraging the advantages of machine learning (ML) and deep learning (DL), AI optimizes applications in structure-based and ligand-based virtual screening, combination drug screening, image analysis, and post-screening data analysis and interpretation, driving the intelligent development of drug discovery. This paper reviews recent research progress in the application of AI in HTS, discusses the implementation of machine learning models, and summarizes key AI applications in HTS-related compound screening, image recognition, and hit identification from complex screening data, aiming to accelerate the development of innovative drugs.

How strong is the evidence?

Evidence Hub reads this as a review, done in computer models (in silico), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free